CAYMAN ISLANDS; UNITED STATES OF AMERICA —MindWalk Holdings Corp. has finalized a binding commitment with Sanabil (Cayman) establishing a senior unsecured revolving credit facility valued at US$30 million. Priced at a fixed annual interest rate of 7.00% applicable solely to drawn capital, the 36-month arrangement includes an option for a 12-month extension via mutual consent. The financing structure omits financial maintenance covenants, warrants, asset pledges, material adverse change closing conditions, and unused line penalties, alongside a single 1.00% opening fee and penalty-free early repayments.
Opting for debt over equity issuance reflects strategic management intent to bypass share dilution amid prevailing market valuations while securing runway for active operational milestones. MindWalk Holdings Corp., trading under NASDAQ: HYFT, operates as a Bio-Native AI enterprise delivering proprietary biological intelligence infrastructure, sequence-structure pattern analytics via HYFT Technology, and downstream application layers including ReefIQ and LensAI for pharmaceutical target discovery. Sanabil (Cayman) functions as a private investment and structured finance entity headquartered in George Town, Cayman Islands.
This non-dilutive infusion shifts the sector trend toward capital-efficient liquidity deployment for platform-heavy AI biotechnology firms facing capital-intensive wet-lab integration cycles. By securing fixed-rate debt without restrictive financial covenants, the enterprise insulates current equity holders from ownership compression while ensuring uninterrupted capital deployment toward proprietary biological data asset compounding and enterprise customer onboarding.
For life sciences equity markets, corporate strategists, and institutional lenders, the facility establishes a benchmark for valuation-independent liquidity sourcing in specialized AI drug-discovery ecosystems. Execution risk centers on finalizing the definitive agreement within the projected 60-day window, commercial adoption velocity for enterprise reasoning tiers, and revenue recognition timing across multi-year pharmaceutical engagements.
